Bausch Investors Initially Pessimistic Following B+L Spinout
Bausch Health Drops 27% Following Q1 Earnings Call
Executive Summary
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
You may also be interested in...
Bausch + Lomb Micronizes Lutein, Zeaxanthin In PreserVision OCUSorb
PreserVision AREDS 2 mini-softgel has proprietary OCUSorb formulation with micronized ingredients in a medium-chain triglyceride oil. More than line extensions, though, are needed for B+L to shed influence from Bausch Health’s credit rating.
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise